JB Chemicals & Pharmaceuticals Limited (JBCPL) records Revenue growth of 19% to Rs.528 crores for Q4 FY2021
Profit After Tax higher by 101% to Rs.101 crores For FY2021, Revenue increases by 15% to Rs. 2,043 crores Profit After Tax higher by 65% to Rs. 449 crores
Chennai, June 15, 2021 – J. B. Chemicals & Pharmaceuticals Limited (JBCPL), one of the fastest-growing pharmaceutical companies in India, announced its financial results for the fourth quarter and financial year ended 31st March, 2021.
Quarterly Financial Performance – Q4 FY21 vs Q4 FY20
For the fourth quarter ended 31st March 2021, the Company recorded revenue of Rs. 528 crores as compared to Rs 444 crores, registering a growth of 19 % over the corresponding quarter ended 31st March, 2020. EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 35% to Rs. 124 crores as compared to Rs.92 crores. EBITDA margin for the quarter was at 23% as compared to 21%. Profit after Tax was higher by 101% at Rs. 101 crores as compared to Rs. 50 crores.
Annual Financial Performance – FY 2021 vs FY2020
For the financial year ended 31st March 2021, the Company recorded revenue of Rs. 2,043 crores as compared to Rs. 1775 crores, registering growth of 15% over the previous financial year ended 31st March, 2020. EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 48% to Rs. 560 crores as compared to Rs. 378 crores. EBITDA margin for FY2021 was at 27% as compared to 21% for FY 2020. Profit after Tax was higher by 65% at Rs. 449 crores compared to Rs. 272 crores.
Earnings Per Share (EPS) was at Rs. 57.96 for FY2021 as compared to Rs. 34.20 for FY2020. The Board of directors recommended a final dividend of Rs. 8 per share.
Commenting on financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, JBCPL said, “Our financial performance for FY21 has been encouraging in one of the most challenging periods in recent history. We are pleased with the strength showcased by all our business units – with the India business continuing to record market-beating growth for the year – backed by a new consolidated go-to-market strategy with therapy diversification plans and strong transformation levers to sustain growth. Our international formulations business has performed well and shows great promise with a focused growth strategy for our key markets, aided by new launches. Overall, our plans of strengthening R&D capabilities to support our medium to long-term growth opportunities and various cost efficiency initiatives instituted over the last year places us well to enhance value for all our key stakeholders.”